Belgian drugmaker UCB has replaced chief executive Roch Doliveux with Jean-Christophe Tellier.
Mr Tellier will also be chairman of the executive committee and a member of the board of directors. His predecessor, Roch Doliveux, stepped down on December 31 2014 after a 10-year tenure.
Since joining the company in 2011, Mr Tellier has played a key role in driving the growth of UCB’s three core products, Cimzia (certolizumab pegol), Vimpat (lacosamide) and Neupro (rotigotine). He brings 25 years of experience in pharma to the role.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze